[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# Arrowhead Research Corporation (ARWR)

Arrowhead Pharmaceuticals initiates Phase 1/2a study of ARO-MAPT for Alzheimer's, marking a significant step in CNS RNAi delivery. The stock hits a 52-week high driven by positive trial news and collaborations.

### About Arrowhead Research Corporation
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing gene-silencing medicines for intractable diseases.  
Arrowhead Research Corporation uses the ticker $ARWR for trading. Listed in the [Stocks](/list/stocks) category within the [Healthcare](/list/stocks/healthcare) sectors.

### Insights
- Arrowhead Research Corporation (ARWR) social dominance hit XXXXXX which is XXX% higher than it's daily average.
- Arrowhead Research Corporation (ARWR) market dominance near a 52-week low at XXXXXXX.
- Arrowhead Research Corporation (ARWR) trading volume is up XXXXXX% from the previous month.
- Arrowhead Research Corporation (ARWR) market cap is up XXXXXX% from the previous X months.
- Arrowhead Research Corporation (ARWR) social dominance is up 1734.15% from the previous X months.
- Arrowhead Research Corporation Price hit a 52-Week high of $XXXXX for the hour

### Price: $XXXXX
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:$arwr/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/$arwr/time-series/close.tsv)  
The stock has surged to a 52-week high, driven by positive news such as the FDA Breakthrough Therapy Designation for Plozasiran and the Novartis collaboration. Increased social media mentions and trading volume further support this upward momentum, despite some lingering valuation concerns.  

24-Hour: XXXX%
7-Day: XXXXX%
30-Day: XXXXX%

1-Year High: $XXXXX on 2025-12-09  
1-Year Low: $XX on 2025-04-08  
  
  
### AltRank: XXX
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:$arwr/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/$arwr/time-series/alt_rank.tsv)  
Arrowhead Research Corporation (ARWR) is currently AltRank #563 based on combined combined social and market metrics
Daily Average: XXX  
X Week: XXX -XXX  
X Month: XXX -XXX  
X Months: XXX -XXXXX  
X Year: XXX -XXX  
1-Year High: XXXXX on 2025-05-30  
1-Year Low: XX on 2025-09-03  
  
  
### Galaxy Score: XXXXX
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:$arwr/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/$arwr/time-series/galaxy_score.tsv)  
Current Value: XXXXX  
Daily Average: XX  
X Week: XX -XX  
X Month: XX -XX  
X Months: XX -X  
X Year: XX -XX  
1-Year High: XX on 2025-09-02  
1-Year Low: XX on 2025-09-16  
  
  
### Engagements: XXXXXX (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$arwr/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$arwr/time-series/interactions.tsv)  
Current Value: XXXXXX  
Daily Average: XXXXXX  
X Week: XXXXXXX -XX%  
X Month: XXXXXXXXX +384%  
X Months: XXXXXXXXX +105%  
X Year: XXXXXXXXX +62%  
1-Year High: XXXXXXX on 2025-11-25  
1-Year Low: XXXXX on 2025-05-17  

Engagements by network (24h):
X: XXXXXX

  
  
### Mentions: XXX (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$arwr/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$arwr/time-series/posts_active.tsv)  
Current Value: XXX  
Daily Average: XXX  
X Week: XXX -XX%  
X Month: XXXXX +155%  
X Months: XXXXX +95%  
X Year: XXXXX +96%  
1-Year High: XXX on 2025-11-28  
1-Year Low: XX on 2025-06-14  

Mentions by network (24h):
X: XXXXX

  
  
### Creators: XXX (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$arwr/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$arwr/time-series/contributors_active.tsv)  
XXX unique social accounts have posts mentioning Arrowhead Research Corporation (ARWR) in the last XX hours which is down XX% from XXX in the previous XX hours
Daily Average: XX  
X Week: XXX -XX%  
X Month: XXX +240%  
X Months: XXXXX +154%  
X Year: XXXXX +70%  
1-Year High: XXX on 2025-06-28  
1-Year Low: XX on 2025-04-28  

The most influential creators that mention Arrowhead Research Corporation in the last XX hours

| Creator                                        | Rank | Followers | Posts | Engagements |
| -------                                        | ---- | --------- | ----- | ----------- |
| [@StockMKTNewz](/creator/twitter/StockMKTNewz) | X    | XXXXXXX   | X     | XXXXX       |
| [@BioBoyScout](/creator/twitter/BioBoyScout)   | X    | XXXXX     | X     | XXXXX       |
| [@RNAiAnalyst](/creator/twitter/RNAiAnalyst)   | X    | XXXXXX    | X     | XXX         |
| [@BiomedicalRX](/creator/twitter/BiomedicalRX) | X    | XXXXX     | X     | XXX         |
| [@wkissel](/creator/twitter/wkissel)           | X    | XXX       | X     | XXX         |
| [@smiuffy](/creator/twitter/smiuffy)           | X    | XXXXX     | X     | XXX         |
| [@BioStocks](/creator/twitter/BioStocks)       | X    | XXXXXX    | X     | XXX         |
| [@eWhispers](/creator/twitter/eWhispers)       | X    | XXXXXXX   | X     | XXX         |
| [@BikeRieder](/creator/twitter/BikeRieder)     | X    | XXXXX     | X     | XXX         |
| [@Bourbon7749](/creator/twitter/Bourbon7749)   | XX   | XXX       | X     | XXX         |

[View More](/list/creators/$arwr/100)
  
  
### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$arwr/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$arwr/time-series/sentiment.tsv)  
Current Value: XX%  
Daily Average: XX%  
X Week: XX% -XX%  
X Month: XX% -XX%  
X Months: XX% -XX%  
X Year: XX% -X%  
1-Year High: XXX% on 2025-06-12  
1-Year Low: XX% on 2025-03-20  

Most Supportive Themes:
- Novartis Deal: (10%) Arrowhead Pharmaceuticals announced the closing of its global license and collaboration agreement with Novartis, receiving an upfront payment and shifting development risk for the ARO-SNCA program.
- Pipeline Progress & Data: (15%) Discussions highlight promising pipeline progress, including potential data releases for programs like ARO-C3 and ARO-MMP7, and comparisons with competitors like Wave Life Sciences (WVE).
- RNAi Technology Focus: (20%) The community is actively discussing the strengths and potential of RNAi therapies, with comparisons to other gene-editing technologies like CRISPR and mentions of Arrowhead's leadership in the space.
  
Most Critical Themes:
- Valuation Concerns: (5%) Some posts question Arrowhead's current valuation, especially in comparison to companies with commercialized drugs, despite its extensive pipeline.
- Competitive Landscape: (10%) The competitive nature of the RNAi and broader biotech space is frequently mentioned, with comparisons to companies like Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), and Alnylam Pharmaceuticals (ALNY).
  
  
  
### Social Dominance: XXXXX%
![Social Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$arwr/c:line/m:social_dominance/iv:1d.svg)  
[Social Dominance 24-Hour Time-Series Raw Data](/topic/$arwr/time-series/social_dominance.tsv)  
Current Value: XXXXX%  
Daily Average: XXXXX%  
X Week: XXXXX% +0.014%  
X Month: XXXX% +0.127%  
X Months: XXXX% +0.142%  
X Year: XXXX% +0.093%  
1-Year High: XXXX% on 2025-12-10  
1-Year Low: XXXXXX% on 2025-06-14  
  
  
### Market Dominance: XXXXX%
![Market Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$arwr/c:line/m:market_dominance/iv:1d.svg)  
[Market Dominance 24-Hour Time-Series Raw Data](/topic/$arwr/time-series/market_dominance.tsv)  
Current Value: XXXXX%  
Daily Average: X%  
1-Year High: XXXXX% on 2025-12-08  
1-Year Low: XXXXX% on 2025-12-09  
  
  
### Market Cap: $XXXXXXXXXXXXX
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:$arwr/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/$arwr/time-series/market_cap.tsv)  
Current Value: $XXXXXXXXXXXXX  
Daily Average: $XXXXXXXXXXXXX  
X Week: $XXXXXXXXXXXXX +$21%  
X Month: $XXXXXXXXXXXXX +$74%  
X Months: $XXXXXXXXXXXXX +$322%  
X Year: $XXXXXXXXXXXXX +$227%  
1-Year High: $XXXXXXXXXXXXX on 2025-12-10  
1-Year Low: $XXXXXXXXXXXXX on 2025-04-08  

### Top Arrowhead Research Corporation Social Posts
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"A preclinical RNAi obesity drug platform is worth $1.2B in bio bucks according to $LLY - this deal establishes a floor for valuing $WVE $ARWR clinical RNAi obesity platforms"  
[X Link](https://x.com/jonesallen99138/status/1998479155332264409) [@jonesallen99138](/creator/x/jonesallen99138) 2025-12-09T19:45Z X followers, XXX engagements


"9/10 Thats why $ARWR is totally miscomped. The right peers are $ALNY and $IONS platforms that repeatedly generate drugs and earn higher multiples"  
[X Link](https://x.com/BioBoyScout/status/1998463023363600721) [@BioBoyScout](/creator/x/BioBoyScout) 2025-12-09T18:41Z 4011 followers, XXX engagements


"7/10 $ARWR partnerships get modeled by BofA as cash flows only. Missing: Takeda Amgen GSK Sarepta all de-risk the platform. That should lift PoS speed and EV across the pipeline"  
[X Link](https://x.com/BioBoyScout/status/1998463019987226883) [@BioBoyScout](/creator/x/BioBoyScout) 2025-12-09T18:41Z 4011 followers, XXX engagements


"8/10 Time horizon bias. Platform biotechs compound for decades not one product cycle. Truncate the long tail and youll always undervalue the business. $ARWR"  
[X Link](https://x.com/BioBoyScout/status/1998463021706887671) [@BioBoyScout](/creator/x/BioBoyScout) 2025-12-09T18:41Z 4011 followers, XXX engagements